BCR–ABL tyrosine kinase inhibitors (TKIs) such as imatinib, nilotinib, or dasatinib, which target the leukemogenic tyrosine kinase related to Philadelphia chromosome, are less effective in the treatment of Ph+ ALL than chronic myelogenous leukemia when used as single agents (1). Here, BCR is linked to acute lymphoblastic leukemia.